Drugs / Sagramostim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05344209 | Aug 2022 → Jul 2025 overdue | non-small cell lung carcinoma | Vestre Viken Hospital Trust | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05421897 Background | Nov 2022 → Jan 2026 overdue | neuroblastoma | Children's Hospital Los Angeles | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sagramostim | “Sagramostim” NCT05421897 ↗ |